Ascenta Therapeutics Highlights Multiple Data Presentations at Upcoming AACR Annual Meeting.SAN DIEGO -- Ascenta Therapeutics, Inc. announced today that its small molecule portfolio of apoptosis-triggering compounds will be featured in three oral presentations and several poster presentations at next week's 2007 Annual Meeting of the American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising. The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational (AACR AACR American Association for Cancer Research AACR Anglo-American Cataloging Rules AACR Australasian Association of Cancer Registries AACR African Armed Conflicts Resolved ), to be held in Los Angeles, California April 14-18, 2007. Ascenta's MDM (Modular Digital Multitrack) An audio recorder that mixes and records multiple tracks of digital audio. The two major MDM technologies are ADAT and DTRS. See ADAT and DTRS. 2 program has been selected for presentation at the "High Impact Late-Breaking Research 1" session on Tuesday, April 17 (Hall A at 3:30pm) and will be presented by Dajun Yang, MD, PhD, Senior Vice President of Research at Ascenta Therapeutics and General Manager of Ascenta's R&D Subsidiary in Shanghai, China. The MDM2 program will also be featured in a talk on Saturday, April 14 (Petree D at 4:15pm) by University of Michigan's Professor Shaomeng Wang, PhD, a co-founder of Ascenta. Preclinical studies of AT-101, Ascenta's clinical stage, oral pan-Bcl-2 inhibitor, will be featured in an oral presentation by Dr. Yang on Wednesday, April 18 and in several poster presentations authored by Ascenta personnel and collaborating investigators. In a collaboration with scientists at Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. , Inc., studies of HGSI's TRAIL receptor agonist monoclonal antibodies in combination with Ascenta's small molecule XIAP XIAP X-linked Inhibitor of Apoptosis inhibitors, will be presented in a poster session on Tuesday, April 17 (1pm-5pm). The full schedule of presentations featuring Ascenta's technology is as follows: [TABLE OMITTED] Founded in 2003, Ascenta is a privately-held biopharmaceutical company that discovers and develops targeted new medicines for the treatment of cancer. The company has offices in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. and Malvern, Pennsylvania, and has a preclinical research facility in Shanghai, China. Its technology, licensed from both the National Institutes of Health and the laboratory of Dr. Shaomeng Wang at the University of Michigan (body, education) University of Michigan - A large cosmopolitan university in the Midwest USA. Over 50000 students are enrolled at the University of Michigan's three campuses. The students come from 50 states and over 100 foreign countries. , is focused on discovering molecules that hit vulnerable targets in endogenous apoptosis pathways to shut down cell growth and proliferation in cancer cells. For additional information on Ascenta Therapeutics, please visit the company's website at www.ascenta.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion